The DOI matches its Crossref record; 28 of the 28 references it cites were found in a registry or an index.
The Effects of Hormone Replacement Therapy and Raloxifene on C-Reactive Protein and Homocysteine in Healthy Postmenopausal Women: A Randomized, Controlled Trial1
Abstract
C-Reactive protein and homocysteine are independent risk factors for the development of cardiovascular disease. This study compared the effects of hormone replacement therapy (HRT) and raloxifene on serum C-reactive protein and homocysteine levels as markers of cardiovascular risk in healthy postmenopausal women. Healthy postmenopausal women (n = 390) were enrolled in a double blind, randomized, placebo-controlled, 6-month trial at eight out-patient sites in the United States. Women were randomly assigned to receive continuous combined HRT (0.625 mg/day conjugated equine estrogen and 2.5 mg/day medroxyprogesterone acetate), raloxifene (60 or 120 mg/day), or placebo for 6 months. C-Reactive protein and homocysteine were measured in baseline and 6-month serum samples. HRT increased C-reactive protein levels by 84% (P < 0.001), whereas raloxifene (60 and 120 mg/day) had no significant effect (−6% and −4%, respectively; P > 0.2). Raloxifene (60 and 120 mg/day) significantly lowered serum levels of homocysteine by 8% (P = 0.014) and 6% (P = 0.024), respectively, similar to the 7% (P = 0.014) reduction obtained with HRT. We conclude that HRT and raloxifene lower serum homocysteine levels to a comparable extent in postmenopausal women. Whereas cardiovascular risk predicted by C-reactive protein in healthy postmenopausal women is not influenced by raloxifene, the relationship between elevated C-reactive protein levels with HRT and cardiovascular disease events requires further study.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Hulley, S. (1998) · JAMA · doi:10.1001/jama.280.7.605 · Cited by 6,216
Valery (1995) · doi:10.1001/jama.1995.03520270033028 · Cited by 2,320
Ridker, P. M., Buring, J. E., Shih, J., Matias, M., & Hennekens, C. H. (1998) · Circulation · doi:10.1161/01.cir.98.8.731 · Cited by 1,642
The Jackknife Estimate of Variance
Efron, B., & Stein, C. (1981) · The Annals of Statistics · doi:10.1214/aos/1176345462 · Cited by 1,436
Postmenopausal Hormone Therapy and Mortality
Grodstein, F., Stampfer, M. J., Colditz, G. A., Willett, W. C., Manson, J. E., Joffe, M., Rosner, B., Fuchs, C., Hankinson, S. E., Hunter, D. J., et al. (1997) · New England Journal of Medicine · doi:10.1056/nejm199706193362501 · Cited by 1,184
Ridker, P. M., Glynn, R. J., & Hennekens, C. H. (1998) · Circulation · doi:10.1161/01.cir.97.20.2007 · Cited by 1,013
C-reactive protein induces human peripheral blood monocytes to synthesize tissue factor
Cermak, J., Key, N., Bach, R., Balla, J., Jacob, H., & Vercellotti, G. (1993) · Blood · doi:10.1182/blood.v82.2.513.513 · Cited by 839
Tracy, R. P., Lemaitre, R. N., Psaty, B. M., Ives, D. G., Evans, R. W., Cushman, M., Meilahn, E. N., & Kuller, L. H. (1997) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/01.atv.17.6.1121 · Cited by 836
Self-citationTHE USE OF A SELF-ADMINISTERED QUESTIONNAIRE TO ASSESS DIET FOUR YEARS IN THE PAST
WILLETT, W. C., SAMPSON, L., BROWNE, M. L., STAMPFER, M. J., ROSNER, B., HENNEKENS, C. H., & SPEIZER, F. E. (1988) · American Journal of Epidemiology · doi:10.1093/oxfordjournals.aje.a114780 · Cited by 802
Macy, E. M., Hayes, T. E., & Tracy, R. P. (1997) · Clinical Chemistry · doi:10.1093/clinchem/43.1.52 · Cited by 797
Self-citation
Cited by
Effects of Raloxifene on Cardiovascular Events and Breast Cancer in Postmenopausal Women
Barrett-Connor, E., Mosca, L., Collins, P., Geiger, M. J., Grady, D., Kornitzer, M., McNabb, M. A., & Wenger, N. K. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa062462 · Cited by 1,048
Selective Estrogen-Receptor Modulators — Mechanisms of Action and Application to Clinical Practice
Riggs, B. L., & Hartmann, L. C. (2003) · New England Journal of Medicine · doi:10.1056/nejmra022219 · Cited by 968
Pradhan, A. D., Manson, J. E., Rossouw, J. E., Siscovick, D. S., Mouton, C. P., Rifai, N., Wallace, R. B., Jackson, R. D., Pettinger, M. B., & Ridker, P. M. (2002) · JAMA · doi:10.1001/jama.288.8.980 · Cited by 680
Barrett-Connor, E., Grady, D., Sashegyi, A., Anderson, P. W., Cox, D. A., Hoszowski, K., Rautaharju, P., Harper, K. D., & for the MORE Investigators (2002) · JAMA · doi:10.1001/jama.287.7.847 · Cited by 577
Self-citationLasofoxifene in Postmenopausal Women with Osteoporosis
Cummings, S. R., Ensrud, K., Delmas, P. D., LaCroix, A. Z., Vukicevic, S., Reid, D. M., Goldstein, S., Sriram, U., Lee, A., Thompson, J., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa0808692 · Cited by 387
C‐Reactive Protein (CRP)‐Lowering Agents
Prasad, K. (2006) · Cardiovascular Drug Reviews · doi:10.1111/j.1527-3466.2006.00033.x · Cited by 272
A pharmacological review of selective oestrogen receptor modulators
Goldstein, S. R. (2000) · Human Reproduction Update · doi:10.1093/humupd/6.3.212 · Cited by 205
Selective estrogen receptor modulators: an update on recent clinical findings
Shelly, W., Draper, M. W., Krishnan, V., Wong, M., & Jaffe, R. B. (2008) · Obstetrical & Gynecological Survey · doi:10.1097/ogx.0b013e31816400d7 · Cited by 193
Growth Hormone and Cardiovascular Risk Factors
Gola, M., Bonadonna, S., Doga, M., & Giustina, A. (2005) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2004-0545 · Cited by 135
Co-morbidity in rheumatoid arthritis
Mikuls, T. R. (2003) · Best Practice & Research Clinical Rheumatology · doi:10.1016/s1521-6942(03)00041-x · Cited by 122
Oral contraceptive use and increased plasma concentration of C-reactive protein
Dreon, D. M., Slavin, J. L., & Phinney, S. D. (2003) · Life Sciences · doi:10.1016/s0024-3205(03)00425-9 · Cited by 75
Yildiz, M. F., Kumru, S., Godekmerdan, A., & Kutlu, S. (2005) · International Journal of Gynecology & Obstetrics · doi:10.1016/j.ijgo.2005.05.005 · Cited by 56
“Similarly, recent findings suggest that doses of 60 mg/d or 120 mg/d of raloxifene do not affect serum hs-CRP concentrations [16].”
BackgroundTeede, H. J., Dalais, F. S., & McGrath, B. P. (2004) · The American Journal of Clinical Nutrition · doi:10.1093/ajcn/79.3.396 · Cited by 52
D'Anna, R., Baviera, G., Corrado, F., Cancellieri, F., Crisafulli, A., & Squadrito, F. (2005) · Acta Obstetricia Et Gynecologica Scandinavica · doi:10.1111/j.0001-6349.2005.00661.x · Cited by 52
Greany, K. A., Nettleton, J. A., Wangen, K. E., Thomas, W., & Kurzer, M. S. (2008) · European Journal of Clinical Nutrition · doi:10.1038/sj.ejcn.1602885 · Cited by 51
Mosca, L. (2001) · Clinical Therapeutics · doi:10.1016/s0149-2918(01)80127-2 · Cited by 18
Combination therapy of raloxifene and alendronate for treatment of osteoporosis in elderly women
Um, M. J., Cho, E. A., & Jung, H. (2017) · Journal of Menopausal Medicine · doi:10.6118/jmm.2017.23.1.56 · Cited by 14
Metadata
- Authors
- Walsh, B. W., Paul, S., Wild, R. A., Dean, R. A., Tracy, R. P., Cox, D. A., & Anderson, P. W.
- Venue
- The Journal of Clinical Endocrinology & Metabolism
- Publisher
- The Endocrine Society
- Published
- 2000-01-01
- Volume
- 85
- Issue
- 1
- Pages
- 214-218
- ISSN
- 0021-972X (ISSN-L)
- 1945-7197
- OpenAlex
- W2079327627
- Cited by
- 326
- References
- 28
- FWCI
- 34.64
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.